Table 1 Demographic characteristics in the GAPP-MDD clinical trial at baseline by treatment in the per-protocol cohort.

From: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

Demographics

Treatment

Total (N = 276)

p-value

TAU (N = 93)

GEN (N = 90)

E-GEN (N = 93)

Age group, n (%)

18 to 34

35 (37.6)

42 (46.7)

32 (34.4)

109 (39.5)

0.21

35 to 49

27 (29.0)

21 (23.3)

32 (34.4)

80 (29.0)

0.26

50 to 64

25 (26.9)

20 (22.2)

25 (26.9)

70 (25.4)

0.71

65 and over

6 (6.5)

7 (7.8)

4 (4.3)

17 (6.2)

0.61

Age

Mean (SD)

42.3 (14.2)

40.3 (15.3)

40.7 (12.9)

41.1 (14.1)

0.62

Min, Max

20.0, 78.0

19.0, 76.0

18.0, 69.0

18.0, 78.0

–

Gender, n (%)

Female

59 (63.4)

59 (65.6)

60 (64.5)

178 (64.5)

0.96

Male

34 (36.6)

31 (34.4)

33 (35.5)

98 (35.5)

0.96

Ethnicity, n (%)a

Asian

7 (7.5)

10 (11.1)

7 (7.5)

24 (8.7)

0.61

Black

1 (1.1)

3 (3.3)

4 (4.3)

8 (2.9)

0.40

Caucasian

83 (89.2)

72 (80.0)

77 (82.8)

232 (84.1)

0.21

Latin American

2 (2.2)

2 (2.2)

1 (1.1)

5 (1.8)

0.81

Other

0

3 (3.3)

4 (4.3)

7 (2.5)

0.15

Depression category, n (%)

Moderate (HAM-D17 14–18)

28 (30.1)

26 (28.9)

30 (32.3)

84 (30.4)

0.88

Severe (HAM-D17 19–22)

25 (26.9)

24 (26.7)

27 (29.0)

76 (27.5)

0.92

Very severe (HAM-D17 > 22)

40 (43.0)

40 (44.4)

36 (38.7)

116 (42.0)

0.71

Psychiatric comorbidities, n (%)

Generalized anxiety disorder

35 (37.6)

45 (50.0)

38 (40.9)

119 (43.1)

0.23

Panic disorder

8 (8.6)

15 (16.7)

15 (16.1)

38 (13.8)

0.21

Post-traumatic stress disorder

7 (7.5)

7 (7.8)

8 (8.6)

22 (8.0)

0.96

HAM-D17

Mean (SD)

21.4 (4.5)

21.3 (4.7)

21.5 (4.8)

21.4 (4.7)

0.99

Min, Max

14.0, 36.0

14.0, 36.0

14.0, 33.0

14.0, 36.0

–

Number of failed psych meds, n

1

28

14

20

62

0.0598

2

20

23

15

58

0.29

3

12

8

14

34

0.44

4

9

17

8

34

0.07

5

8

7

10

25

0.77

6+

13

20

24

57

0.12

Missingb

3

1

2

6

0.62

Mean (SD)

3.0 (2.2)

3.7 (2.2)

4.0 (3.1)

3.6 (2.6)

0.0388

Min, Max

1.0, 9.0

1.0, 8.0

1.0, 21.0

1.0, 21.0

–

  1. aExpanded ethnicity groupings are presented in Supplementary Tables 10–12.
  2. bPatient who reported failing ≥1 prior medication trial, but did not report specific number of prior failed trials.
Back to article page